Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 16/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203631 | 0.93 | HPGD (0.54) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL203000 | 0.91 | HPGD (0.51) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL205401 | 0.90 | HPGD (0.51) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL205119 | 0.90 | HPGD (0.51) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL203569 | 0.90 | HPGD (0.51) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL204546 | 0.89 | HPGD (0.49) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL205690 | 0.88 | HPGD (0.49) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL203514 | 0.87 | HPGD (0.48) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL202725 | 0.85 | ALDH1A1 (0.45) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL205811 | 0.83 | ALDH1A1 (0.54) | HPGDALDH1A1KDM4ECYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3428148-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3088384-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2010056999-A9 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3088384-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2155699-B9 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050874-A1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2639228-B1 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8461176-B2 | Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8283475-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8088801-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2364301-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial Limited (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010056999-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
| EP-2155699-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial Limited (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008144275-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | HPGD 3406/4885ALDH1A1 1677/4885KDM4E 77/4885 |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | HPGD 3406/4885ALDH1A1 1677/4885KDM4E 77/4885 |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4B1, NPY4R, CYP4X1 | HPGD 3557/4885ALDH1A1 1144/4885KDM4E 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.